Pfizer opens the week with a clear earnings calendar, shares on NYSE in focus

Pfizer opens the new trading week with a visible slot in the upcoming earnings calendar while its shares continue to trade on the NYSE with a large-cap healthcare profile.

By Mark Bergmann, Earnings & Calendar desk. Reviewed prior to publication on 2026-06-30, 12:23.

Pfizer Inc. (US7170811035) starts this week with investors looking ahead to its next quarterly earnings release. The US pharmaceutical group is listed on the NYSE and ranks among the largest constituents in the S&P 500 healthcare sector.

What the earnings calendar shows

Pfizer typically reports its quarterly results on a regular rhythm aligned with the broader US reporting season, with updates on revenue, earnings per share and pipeline progress. In the week ahead, investors focus on the expected timing of the second-quarter 2026 numbers and management commentary on post-pandemic revenue trends.

For many retail investors, the recurring earnings dates structure the year, as Pfizer's reports offer new detail on prescription drug sales, vaccine revenues and cost management. The calendar-based visibility on upcoming numbers helps investors compare Pfizer with other large-cap US healthcare peers such as Johnson & Johnson and Merck.

Consensus expectations on Pfizer

On the analyst side, consensus expectations for Pfizer's coming quarters typically combine forecasts on total revenue, adjusted earnings per share and margin development. Large houses such as Goldman Sachs, JPMorgan and Morgan Stanley publish regular updates, setting rating and price-target frameworks that many market participants monitor.

Across Wall Street, the distribution of ratings on Pfizer generally spans Buy, Hold and occasionally Sell, reflecting differing views on the sustainability of vaccine-related cash flows versus the core drug business. The consensus picture helps frame whether upcoming earnings are seen as an opportunity or a risk for the shares at current levels.

How Pfizer makes its money

Pfizer generates revenue predominantly from patented prescription medicines and vaccines across therapeutic areas including oncology, cardiology, immunology and infectious diseases. A representative product in the current portfolio is the pneumococcal vaccine Prevnar, which addresses prevention of serious bacterial infections and forms part of routine vaccination schedules in many markets.

Where the stock trades today

Pfizer Inc. shares (US7170811035) trade on the NYSE in US dollars. As of 2026-06-30, 12:23, the shares change hands at a recent level in the mid-teens to low-twenties dollar range, reflecting its status as a large-cap healthcare stock with broad index membership.

Key data on the Pfizer shares

• Company: Pfizer Inc.
• ISIN: US7170811035
• WKN: 852009
• Ticker: PFE
• Trading venue: NYSE
• Price (as of 2026-06-30, 12:23): recent level in the mid-teens to low-twenties US dollars
• Market cap: large-cap level in the tens of billions of US dollars (as of 2026-06-30)
• Sector / industry: Healthcare / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: not officially scheduled

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.